Evidence map›Paper›PMID 37662410›Full record

ArticlebioRxiv : the preprint server for biology2023

Human plasma cells engineered to secrete bispecifics drive effective

Tyler F Hill, Parnal Narvekar, Gregory Asher, Nathan Camp, Kerri R Thomas, Sarah K Tasian, David J Rawlings, Richard G James

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tyler F HillUniversity of Washington, Medical Scientist Training Program, Seattle WA.
Parnal NarvekarSeattle Children's Research Institute, Center for Immunity and Immunotherapy, Seattle WA.
Gregory AsherSeattle Children's Research Institute, Center for Immunity and Immunotherapy, Seattle WA.
Nathan CampSeattle Children's Research Institute, Center for Immunity and Immunotherapy, Seattle WA.
Kerri R ThomasSeattle Children's Research Institute, Center for Immunity and Immunotherapy, Seattle WA.
Sarah K TasianChildren's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, Philadelphia PA.
David J RawlingsSeattle Children's Research Institute, Center for Immunity and Immunotherapy, Seattle WA.
Richard G JamesSeattle Children's Research Institute, Center for Immunity and Immunotherapy, Seattle WA.
University of Washington · USChildren's Hospital of Philadelphia · US

Funding

Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphomaR01CA201135 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI JAMES, RICHARD GOFF · 2017 to 2021
$2.1M
Developing Monoclonal Antibody Secreting Human Plasma Cells to Provide Long-Lasting EBV Immunity in Humanized MiceF30AI164574 · NIAID · UNIVERSITY OF WASHINGTON · PI HILL, TYLER F · 2021 to 2025
$171k
NCI NIH HHS R01 CA201135NIAID NIH HHS F30 AI164574
6 · The paper itself

Abstract

Bispecific antibodies are an important tool for the management and treatment of acute leukemias. Advances in genome-engineering have enabled the generation of human plasma cells that secrete therapeutic proteins and are capable of long-term

Identifiers

PMID37662410
PMCPMC10473709
OpenAlexW4386202950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.